Del11q ATM MM CLL FISH Test
Comprehensive Genetic Testing for Blood Cancers
The Del11q ATM MM CLL FISH Test represents a cutting-edge diagnostic approach in modern oncology, specifically designed to detect critical genetic abnormalities associated with multiple myeloma (MM) and chronic lymphocytic leukemia (CLL). This advanced genetic screening utilizes fluorescence in situ hybridization (FISH) technology to identify deletions in the ATM gene located on chromosome 11q, providing invaluable insights for cancer diagnosis and management.
What Does This Test Measure?
This specialized FISH test specifically targets and detects:
- Deletions in the ATM (ataxia-telangiectasia mutated) gene on chromosome 11q
- Genetic abnormalities associated with multiple myeloma progression
- Chromosomal changes relevant to chronic lymphocytic leukemia development
- Specific 11q deletions that impact treatment response and prognosis
Who Should Consider This Test?
Clinical Indications and Symptoms
This test is particularly important for individuals experiencing:
- Unexplained fatigue, weakness, or persistent tiredness
- Frequent infections or compromised immune function
- Unexplained weight loss or night sweats
- Bone pain, particularly in the back or ribs
- Enlarged lymph nodes or spleen
- Abnormal blood counts suggesting hematological disorders
- Existing diagnosis of multiple myeloma or CLL requiring genetic profiling
- Family history of hematological cancers
Benefits of Del11q ATM Testing
Comprehensive Diagnostic Advantages
- Accurate Diagnosis: Provides definitive genetic confirmation of specific cancer subtypes
- Prognostic Information: Helps predict disease progression and patient outcomes
- Treatment Guidance: Informs targeted therapy selection and treatment strategies
- Risk Stratification: Identifies patients who may benefit from more aggressive treatment approaches
- Monitoring Tool: Enables tracking of disease evolution and treatment response
- Personalized Medicine: Supports development of individualized treatment plans
Understanding Your Test Results
Interpreting Genetic Findings
Your test results will be carefully analyzed and interpreted by our expert genetic specialists:
- Positive Result: Indicates presence of 11q deletion, which may influence treatment decisions and prognosis
- Negative Result: Suggests absence of the specific genetic abnormality tested
- Complex Results: May require additional testing or consultation for comprehensive interpretation
- Clinical Correlation: Results should always be interpreted in context with clinical findings and other diagnostic tests
Our genetic counselors and oncology specialists will provide detailed explanations of your results and their implications for your treatment plan.
Test Details and Pricing
| Test Parameter | Details |
|---|---|
| Test Name | Del11q ATM MM CLL FISH Test |
| Regular Price | $176 USD |
| Discount Price | $132 USD |
| Turnaround Time | 3-4 Days |
| Sample Type | Bone Marrow / Peripheral Blood |
| Test Components | Sodium Heparin Vacutainer (2ml) |
| Testing Method | Fluorescence In Situ Hybridization (FISH) |
Nationwide Testing Availability
GGC DNA provides comprehensive genetic testing services across the United States, with convenient locations in major metropolitan areas including:
- New York City and surrounding areas
- Los Angeles and Southern California
- Chicago and the Midwest region
- Houston and Texas metropolitan areas
- Miami and South Florida
- Seattle and Pacific Northwest
- Boston and New England region
- Atlanta and Southeastern states
Take Control of Your Health Today
Don’t wait to get the critical genetic information you need for informed cancer management. Our Del11q ATM MM CLL FISH Test provides essential insights that can significantly impact your treatment journey and overall outcomes.
Ready to schedule your test? Contact us today:
Phone: +1(267) 388-9828
WhatsApp: +1(267) 388-9828
Our dedicated team is available to answer your questions, discuss testing requirements, and help you schedule your appointment at a location convenient for you. Take the first step toward comprehensive genetic understanding and personalized cancer care.
